Loading…
H.R. 8339119th CongressIn committeeLatest action Apr 16, 2026Decoded by AI · checked against the record
Official title: Drug Origin Transparency Act of 2026
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
HR 8339 would require drug makers to report ingredient sources to the government and display that information on drug labels.
50-second read · 4 questions answered below
This bill requires drug manufacturers to tell the federal government who supplies each ingredient in their drugs and how much of the drug came from each supplier. Reports could be required up to four times a year. Drug labels and package documents would also have to show the name, location, and a unique ID number for every company involved in making, packing, or distributing the drug.
Drug manufacturers, ingredient suppliers, and distributors would face new reporting and labeling requirements. Consumers and pharmacists would be able to see more detail about where drugs and their ingredients are made.
Because more sourcing information would appear on labels and in government reports, the origin of a drug and its ingredients would be more traceable. The Food and Drug Administration would be responsible for writing the rules that define exactly what must be reported and how it must appear on labels.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the House Committee on Energy and Commerce.